First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody
Structural analysis of light chain-driven bispecific antibodies targeting CD47 andPD-L1
Antibody Engineering & Therapeutics Europe- Sara Majocchi -
- Two Light chain Bioscience presentations at Antibody Engineering & Therapeutics Europe
- PEGS Boston – Advancing Bispecific Antibodies and Combination Therapy to the Clinic
- AACR-2023 NI-2901 (CD47xPD-L1) & NI-3201 (CD28xPD-L1) bispecific antibodies
- Keystone Symposia – Next Generation Antibody Therapeutics: From Discovery to Patient
